参考文献/References:
1 Uy HL,Reasner CA,Samuels MH.Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves disease[J Am J Med,1995,99:173-179.
2 Giovanella L,D e palma D,Ceriani L,et al.Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach:Clinical results[J].Radiol Med(Torino),2000,100(6):480-483.
3 Andrade VA,Gross JL,Maia AL.The effect of mothimazole pretreatment on the efficaly of radioactive iodine therapy in Graves’ hyperthyroidism:one-year of follow-up of a prospective,randomized study[J].J Clin Endocrinol M etab,2001,8(8):3488-3493.
4 Ghadban WK,Zirie MA,AL-Khateeb DA,et al.Radioiodine treatment of hyperthyroidism:success rate and influence of thyrostaticm edication[J].Saudi Med J,2003,24(4):347-351.
5 Ahmad AM,Ahmad M,Young ET.Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis[J].Eur J Endocrinol,2002,146(6):767-775.
6 Gomez JM,Gomez N,Amat M,et al.Hypothyroidism after iodine-131 or surgical therapy for Graves’ disease hyperthyroidism[J].Ann Endocrinol(paris),2000,61(3):184-191.
7 Holm LE,Lundell G,Israesson A,et al.Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthy-roidism[J].J Nucl Med,1982,23(2):103-107.
8 Bringmann IM,Van leeuwen BL,Hennemann G,et al.Outcome of treatment of hyperthyroidism[J].J Endocrinol Invest,1999,22(4):250-256.
9 Yoshimoto M,Iino S,Yoshimura H,et al.A five-year follow-up of two different 131I treatment methods for Graves’ disease and the factors affecting the outcome[J].J Nippon Naibupi Gakkai Zasshi,1998,70(9):995-1006.
10 Gomez N,Gomez JM,Orti A,et al.Transient hypothyroidism af-teriodine-131 therapy for Graves’ disease[J].J Nucl Med,1995,36(9):1539-1542.
11 Sabri O,Schulz G,Zimny M,et al.Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients radioactive iodine with Graves’ disease[J].Nuklearmedizin,1998,37:83-84.
12 Sabri O,Zimny M,Schreekenbergerm,et al.Characterization of the rapy failures in radioidine therapy of Grave’s disease without antithyroid agents[J].Nuklearmedizin,2001,40(1):1-6.
13 Gibold L,Delisle MJ,Maes B.Treatment of hyperthyroidism by radioactive iodine:Development of methods and difficulties in the surveillance[J].Presse Med,1988,17(17):1397-1400.
14 Lesie W D,Peterely AE,Dupout JD.Radioiodine therapy treatment in thyroid glands previously irradiated for Graves’ hyperthyroidism[J].J Nucl Med,1998,39(4):712-716.
15 Chiovato L,Fiore E,Vitti P,et al.Outcome of thyroid function in Grave’s patient with radioidin:role of thyroid-stimulating and thyrotropin-blocking antibodies and radioiodine-induced thyriod dam-age[J].J Clin Endocrinol Meted,1998,83(1):40-46.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]贾强,孟召伟,谭建.异位甲状腺发病机理、诊断与治疗的研究进展[J].国际放射医学核医学杂志,2016,40(4):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
Jia Qiang,Meng Zhaowei,Tan Jian.Progress of pathogenisis, diagnosis and treatment of ectopic thyroid[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
[4]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[5]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[6]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[7]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[8]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[9]孟召伟,谭建.美国甲状腺协会和临床内分泌医师协会2012年甲减诊治指南介绍[J].国际放射医学核医学杂志,2013,37(2):124.[doi:10.3760/cma.j.issn.1673-4114.2013.02.016]
MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hypothyroidism published in 2012 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):124.[doi:10.3760/cma.j.issn.1673-4114.2013.02.016]
[10]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[11]郭永铁.促甲状腺激素与亚临床性甲状腺功能异常[J].国际放射医学核医学杂志,2008,32(6):351.
GUO Yong-tie.Thyroid stimulating hormone and subclinical thyroid dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):351.
[12]王金萍,吴秋莲,徐浩.甲状腺功能与血清饥饿素和瘦素水平的相关陛研究[J].国际放射医学核医学杂志,2008,32(4):221.
WANG Jin-Lian,WU Qiu-lion,XU Hao.Association of thyroid function with human serum ghrelin and leptin levels[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):221.
[13]李诗运.131I治疗甲亢后甲减的综合预防和处理措施[J].国际放射医学核医学杂志,2004,28(4):157.
LI Shi-yun.Synthetic prevention and treatment for hypothyroidism after rdioiodine therapy hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):157.